MUSSALLEM MICHAEL A 4

4 · Edwards Lifesciences Corp · Filed May 2, 2024

Form 4

Period: 2024-05-02

DirectorChairman & CEO

Transactions

Exercise/Conversion
Common Stock
2024-05-02$36.75/sh+29,350$1,078,613→ 33,835.82 total
Sale
Common Stock
2024-05-02$85.02/sh−12,207$1,037,839→ 21,628.82 total
Exercise/Conversion
Employee Stock Option (Right to Acquire)
2024-05-02−29,350→ 0 total
Exercise: $36.75From: 2017-06-11Exp: 2024-05-10→ Common Stock (29,350 underlying)
Sale
Common Stock
2024-05-02$84.59/sh−17,143$1,450,126→ 4,485.82 total

Holdings

Footnotes (3)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
[F2]This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
[F3]This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file